Introduction
============

In April 2009, the US Patent and Trademark Office (PTO) granted its 50,000th DNA patent, making at least one claim about DNA or RNA molecules or their uses \[[@B1]\]. A gene patent, as the term is generally used, is a DNA patent that claims rights over nucleic acid sequences encoding proteins, or variants of those sequences. Jensen and Murray \[[@B2]\] identified 4,270 US patents granted by the end of 2004 that explicitly claimed DNA sequences for 4,382 out of 26,688 (approximately 20%) human genes catalogued in the RefSeq database. Another study found 16,000 DNA-sequence patents were granted worldwide, with the US PTO granting almost ten times more such patents than either the European or Japanese patent offices from 1980 to 2003 \[[@B3]\].

Gene patents have been of particular interest because of their relevance to biopharmaceuticals and genetic diagnostics. Gene patents underpin production of therapeutic biologic products such as insulin, growth hormone, erythropoietin and other growth factors, or of specific antibodies for biological therapy. Some therapeutic gene patents have been the subject of litigation \[[@B4]\] but there has been relatively little public controversy, perhaps because such patents act much like those on small-molecule drugs.

In contrast, gene patents have repeatedly sparked controversy in the context of genetic testing for Mendelian disorders and mutations predicting risk of common chronic diseases. Media coverage has been predominantly negative. Testing *BRCA1*and *2*gene variants to predict inherited risk of breast and ovarian cancer has been particularly controversial, with overwhelmingly negative press coverage, except in Utah, home to Myriad Genetics, the company with exclusive rights to perform diagnostic testing \[[@B5]\]. In May 2009, a consortium of plaintiffs supported by the American Civil Liberties Union filed a lawsuit in federal court in New York against Myriad Genetics and other defendants \[[@B6]\]. Because this lawsuit challenges the validity of claims on isolated nucleotide sequences, the final ruling on the suit could affect the validity of numerous other patents with similarly structured claims for genetic diagnostics as well as therapeutics. Concerns raised about the effects of gene patents on diagnostics include sole provider companies\' ability to set a *de facto*national standard of clinical care, higher costs, lower quality, inhibition of better testing methods, impediments to clinical research, and limitations on medical professionals\' education.

Studies and policy reports on gene patents
==========================================

Over the past decade, the UK\'s Nuffield Council of Bioethics \[[@B7]\], the Australian Law Reform Commission \[[@B8]\], the Organization of Economic Co-operation and Development \[[@B9]\] and the European Society of Human Genetics \[[@B10]\] have prepared policy reports on how patents affect genetic diagnostics. Several case studies suggest that patents and exclusive licensing have reduced the availability of genetic testing for hereditary hemochromatosis, Canavan\'s disease, and breast cancer \[[@B11]-[@B17]\]. In addition, responses to laboratory surveys indicate that patent enforcement has reduced the number of providers for some patented genetic tests \[[@B11],[@B17]\].

The Secretary\'s Advisory Committee on Genetics Health and Society (SACGHS, US Department of Health and Human Services) is preparing a policy report addressing the effects of patenting and licensing on clinical access to genetic testing in the United States. The SACGHS released a draft report for public comment in March \[[@B18]\], and is likely to release the final report late this year or early in 2010. Our group at Duke University gathered empirical evidence for the SACGHS at the committee\'s request. We concluded that it is difficult to make evidence-based claims that patents have either substantially helped or hindered clinical and patient access to genetic testing in the US \[[@B19]\].

It is not just what is patented that matters, but how patents are used
======================================================================

Patenting and licensing of patents relevant to DNA diagnostics interact in complex ways with the US healthcare system. Problems arise when patents covering genetic tests are licensed exclusively to a single test provider and no alternative avenue for testing is available. When the provider does not offer all forms of genetic testing (for example, preimplantation or prenatal testing or testing of paraffin-embedded tissues), or does not have coverage and reimbursement agreements with insurers or health plans, patients cannot turn elsewhere to get a test. Moreover, firms with *de facto*monopolies on testing for certain conditions have no explicit policies to clarify that they support basic and clinical research, verification of results and \'second opinion\' testing, and transparent, independent proficiency testing and quality control. It bears emphasis, however, that case studies of current genetic testing cannot fully predict what issues are likely to arise for future DNA diagnostic technologies.

Genomic diagnostics: past experience may not predict future uses
================================================================

Technologies for genotyping, gene expression profiling and full-genome sequencing are advancing with extraordinary rapidity, promising to displace genetic testing methods that have been fairly stable for a decade. New classes of diagnostics can simultaneously detect millions of genetic variations and mutations, and expression-level changes in thousands of genes, or even the entire genome. Genomic diagnostics are beginning to realize the promise of personalized medicine as they increasingly guide choices among treatments, drug doses and preventive interventions for cancer, heart disease, diabetes and infectious diseases.

Navigating the complex intellectual property landscape of DNA patents poses challenges for genomic diagnostics. Multi-gene diagnostic tests may infringe existing DNA-sequence or method claims, and difficulty in securing freedom to operate could slow some promising clinical technologies. Concerns include difficulties in aggregating rights to many patent claims and costs of procuring multiple licenses (royalty-stacking), often described as the anticommons effect, and securing rights already exclusively licensed to others by prior agreement (blocking problems). To date, less than 1% of US \'gene patents\' have spawned litigation. This frequency is comparable to patents in general (1 to 2%). Only five cases have involved genetic diagnostics and all five were settled before going to trial \[[@B4]\]. The rarity of litigation and the complete absence of precedent-setting case law for DNA diagnostics, however, does not imply that patents have no effect. In many cases, it is clear that simply sending letters threatening patent enforcement is sufficient to \'clear the market\' of competitors in genetic testing \[[@B20]\]. Litigation is very costly, and many of the relevant economic effects may be lower than the threshold cost of either bringing or fighting a lawsuit. As DNA diagnostics become more valuable and the stakes get big enough to fight about, litigation might become more common. Moreover, the few cases of litigation have involved traditional genetic testing, and not the emerging multi-gene diagnostics. Those developing such new diagnostic technologies are flying in the dark.

Shifting jurisprudence
======================

Uncertainty about DNA diagnostic patents is compounded by shifts in patent practice and jurisprudence. The US PTO announced higher thresholds for utility and written description of sequence-based patent claims in 1999 and implemented them in early 2001 \[[@B21],[@B22]\]. Recent decisions by the US Court of Appeals for the Federal Circuit and the US Supreme Court have raised the standard for obviousness (*KSR International Co.*v. *Teleflex Inc.*) \[[@B23]\], changed criteria for allocating damages for patent infringement proportional to the actual contribution of the patented invention under dispute, and made automatic injunctions more discretionary (*eBay Inc.*v. *MercExchange LLC*) \[[@B24]\]. Two pending cases, *Bilski*v. *Kappos*(expected to be decided by the Supreme Court in 2010) \[[@B25]\], and the recent Appeals Court decision in *Prometheus*v. *Mayo*\[[@B26]\] promise to be directly relevant to DNA diagnostics, and could change the game. In Europe, there has been even less litigation over diagnostics, and far less patent enforcement than in the US, but commercial genetic testing may become more important there in coming years \[[@B27],[@B28]\].

The future of patents and diagnostics: continued uncertainty and increasing complexity
======================================================================================

Our preliminary analysis suggests that microarray-based methods of genetic analysis for many genes and gene variants, and *a fortiori*full-genome sequencing could arguably infringe on some patent claims. However, such claims have never been tested in court, and some appear vulnerable to changing interpretations of what can be patented, so it is difficult to know if they would be held valid if challenged. While much of the attention has focused on patents claiming nucleic acid sequences, claims on specific methods for analyzing or detecting DNA variants are at least as important. In a recent analysis of claims for patents associated with 22 commonly administered genetic tests, van Overwalle and colleagues \[[@B29]\] determined that method claims covering these diagnostics could be harder to \'invent around\' than claims on cDNA sequences. A 2006 study \[[@B30]\] showed growth in patents claiming research tools such as methods for gene expression profiling or detecting single nucleotide polymorphisms and even algorithms and software for disease prediction, classification and prognosis. Some patents claim associations between DNA sequences and clinical conditions or medical outcomes and could also prove difficult to work around.

There is no consensus about whether DNA sequence patents hinder or help in the development and availability of genetic diagnostics, and empirical evidence about how these patents may affect commercialization of new genomic diagnostics is scarce. This seemingly innocuous statement is an advance in the public debate, given that the alleged negative consequences and benefits of patents have so often been grossly overstated. The framework for genetic testing is likely to change within the next decade, as the cost of individual whole-genome sequencing drops to levels comparable to current genetic tests for individual conditions. The forthcoming SACGHS report may have a salutary effect on norms and practices in patenting and licensing of technologies relevant to emerging DNA diagnostics, merely by shining a spotlight on them.
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